Showing results (3251-3260 of 3,662) with videos related to

Sort By:
Pageof 367
Breast (Edinburgh, Scotland)|September 26, 2025
FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation?Armando Orlandi
Breast (Edinburgh, Scotland)|January 7, 2026
Baseline systemic inflammatory indices predict late radiation-induced fibrosis and toxicity in patients with early breast cancerLorenzo Vinante, Jerry Polesel, Andrea Sacilotto, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastasesPeter H Wessels, Sten Cornellisen, Kim Monkhorst, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II studyChristina Engebrethsen, Synnøve Yndestad, Mari E Rasmussen, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
A prognostic gene model with psychological stress-related genes captures immune activation in breast cancerTian Du, Jiayi Tang, Hanqi Zhang, et al.
Breast (Edinburgh, Scotland)|February 6, 2026
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 studyClaudia Noto, Lorenzo Foffano, Fabiola Giudici, et al.
Breast (Edinburgh, Scotland)|April 27, 2025
Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapyXiaoyan Wu, Xunxi Lu, Wenchuan Zhang, et al.
Breast (Edinburgh, Scotland)|April 12, 2025
CADONOT: Comparing axillary dissection or not in breast cancer surgeryAndré Mattar, Marcelo Antonini, Francisco Pimentel Cavalcante, et al.
Breast (Edinburgh, Scotland)|April 12, 2025
Biomarker alteration following chemotherapy-based systemic therapy in de novo metastatic breast cancerLingjun Kong, Chongxi Ren
Breast (Edinburgh, Scotland)|April 9, 2025
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world studyXuenan Peng, Bo Lan, Jiayu Wang, et al.
Pageof 367